Place of @entity9229 in XXXX : a meta-analysis.

@entity1 @entity9229 @entity442 @entity2012 @entity1943
CONTEXT: @entity9229 is widely considered to be poorly effective in @entity2012 . OBJECTIVE: The aim of this study was to obtain a more accurate picture of the efficacy of @entity9229 in @entity2012 , both alone and in combination with @entity1943 analogs. DESIGN: We systematically reviewed all trials of @entity9229 therapy for @entity2012 published up to 2009 in four databases (PubMed, Pascal, Embase, and Google Scholar). We identified 15 studies (11 prospective) with a total of 237 @entity1 ; none were randomized or placebo-controlled. A meta-analysis was conducted on individual data (n = 227). RESULTS: @entity9229 was used alone in nine studies. Fifty-one (34%) of the 149 @entity1 achieved normal @entity442 levels. In multivariate analysis, the decline in @entity442 was related to the baseline @entity442 concentration (b = 1.16; P <0.001), treatment duration (b = 0.28; P < 0.001), and baseline prolactin concentration (b = -0.18; P = 0.01), and with a trend toward a relation with the @entity9229 dose (b = 0.38; P =0.07). In five studies, @entity9229 was added to ongoing @entity1943 analog treatment that had failed to normalize @entity442 . Forty @entity1 (52%) achieved normal @entity442 levels. The change in @entity442 was significantly related to the baseline @entity442 level (b = 0.74; P < 0.001) but not to the dose of @entity9229 , the duration of treatment, or the baseline prolactin concentration. CONCLUSION: This meta-analysis suggests that @entity9229 single-agent therapy normalizes @entity442 levels in one third of @entity1 with @entity2012 . When a @entity1943 analog fails to control @entity2012 , @entity9229 adjunction normalizes @entity442 in about 50% of cases. This effect may occur even in @entity1 with normoprolactinemia.
